EFFECTS OF LIRAGLUTIDE [amount hidden] ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS

What Was Tested

The paper reports a study of Liraglutide, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The researchers conducted the double-blind randomized, placebo-controlled trials in adults with a minimum body mass index (BMI) of 27 kg/m2 with at least 1 comorbidity, or a minimum BMI of 30 kg/m2, at clinical research sites worldwide.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Liraglutide.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

Variables examined included mean and categorical weight change, cardiovascular risk markers, and safety data.

What Was Measured

The subject headings attached to it are Comorbidity, Hispanic or Latino, Hypoglycemic Agents, Liraglutide, Obesity, Outcome Assessment, Health Care and Overweight.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Liraglutide compound page.